Our latest release adds an integrated suite of molecular biology tools, a chemical registry, and support for antibody-drug conjugates
StackWave Affinity 18 adds essential molecular biology tools, and support for bioconjugates, including ADCs, fully integrated with the rest of Affinity's modules for planning, discovery, expression, inventory, characterization, and reporting. With this release, we continue to deliver on our promise of providing the most comprehensive R&D platform available, now for both biologics and small molecule teams, with more exciting improvements around the corner.
Every registered protein and peptide, as well as databases of elements that your team defines, are available for building new vectors. These elements are also automatically identified in newly-registered plasmids and proteins, and are both highlighted in Affinity's sequence visualization tools and made searchable throughout the software.
Visually design your vectors by importing sequence files, pasting sequence fragments, or inserting sequence elements from the parts catalog. Affinity will perform reverse-translation on any protein and peptide elements for which no DNA exists, optionally codon-optimizing it for the expression host of your choice. Vectors can then be registered directly into the bioregistry and become immediately available for subsequent cloning and expression.
Affinity can now simulate the process of cloning your proteins into backbone vectors of your choice. Select your cloning method and provide a few related details to Affinity (or accept any defaults your team has already set), and Affinity will generate a corresponding set of inserts and expected plasmid sequences. Use these simulated sequences to generate order forms for CROs or to guide your in-house synthesis and cloning operations. Once cloned, review your AB1 traces directly in Affinity; the system will also compare your trace with the expected sequence to guide you in sequence verification.
We have always been proud of Affinity's comprehensive support for biologics teams, but biologics is still only one part of drug discovery. Medicinal chemistry has delivered critical, blockbuster medicines for decades, and for the first time Affinity now supports medicinal chemists as well. We bring all of the same tools to bear on small molecule drug discovery, providing out-of-the-box support for registration, inventory management, characterization, in-vivo studies, and reporting. Register compounds in bulk via SMILES, or sketch your compounds using our built-in chemical sketcher.
StackWave is constantly building towards greater and greater flexibility in designing and working with novel therapeutics, and our latest release extends that flexibility into the realm of antibody-drug conjugates (ADCs). Affinity's support for chemical compounds enables registration and management of antibody-drug conjugates in Affinity's bioregistry, and as with any other reagent in the registry, ADCs in Affinity enjoy out-of-the-box support for registration, inventory management, characterization, in-vivo studies, and reporting.
If you'd like to see these new capabilities in action, please request a demo.
We are excited to announce the release of StackWave Affinity™ v13! Highlights include integrated ELN and nanobody support.
StackWave Affinity v15 Announcement - Titration and Dose Response Experiments
We are excited to announce the release of StackWave Affinity™ v13! Highlights include custom dashboard and reporting tools and a REST API.